{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:47:12Z","timestamp":1788184032642,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two DLs of venetoclax were evaluated with an expansion cohort at the recommended phase 2 dose. Twenty-five patients were enrolled. The recommended phase 2 dose was venetoclax 800 mg OD continuously for 6 cycles starting on day 2 of cycle 1, with obinutuzumab 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 to 6, followed by obinutuzumab maintenance every 2 months for 2 years. Only 1 patient had a DLT consisting of grade 4 thrombocytopenia after the first obinutuzumab infusion. Neutropenia was the most common adverse event of grade \u22653 at least possibly attributed to study treatment. Twenty-four patients were evaluable for response after cycle 6 by computed tomography (CT) and 19 by positron emission tomography\/CT (PET\/CT): overall and complete response rates were 87.5% (95% CI, 67.6% to 97.3%) and 25% (95% CI, 9.8% to 46.7%) in the CT-evaluated patients and 84.2% (95% CI, 60.4% to 96.6%) and 68.4% (95% CI, 43.4% to 87.4%), respectively, in the PET\/CT-evaluated patients. One-year progression-free survival was 77.8% (95% CI, 54.6% to 90.1%) and 79% (95% CI, 47.9% to 92.7%) for CT and PET\/CT-evaluable patients, respectively, whereas progression-free survival at 30 months was 73.2% (95% CI, 49.8%, 87.0%) as assessed by CT and 79.0% (95% CI, 47.9%, 92.7%) by PET\/CT. Despite the activity observed, our results do not support further development of the combination in this patient population. This trial was registered at www.clinicaltrials.gov as #NCT02877550.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006520","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T19:53:01Z","timestamp":1652212381000},"page":"3911-3920","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["SAKK 35\/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma"],"prefix":"10.1182","volume":"6","author":[{"given":"Anastasios","family":"Stathis","sequence":"first","affiliation":[{"name":"1Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mey","sequence":"additional","affiliation":[{"name":"2Oncology and Hematology, Kantonsspital Graubuenden, Chur, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e4mi","family":"Sch\u00e4r","sequence":"additional","affiliation":[{"name":"3SAKK Coordinating Center, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Hitz","sequence":"additional","affiliation":[{"name":"4Oncology\/Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[{"name":"5Medizinischen Klinik II H\u00e4matologie und Internistische Onkologie, Universit\u00e4tsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-1088","authenticated-orcid":false,"given":"Nicolas","family":"Mach","sequence":"additional","affiliation":[{"name":"6Service d'Oncologie, D\u00e9partement d'Oncologie, H\u00f4pitaux Universitaires de Gen\u00e8ve, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatime","family":"Krasniqi","sequence":"additional","affiliation":[{"name":"7Medical Oncology, University Hospital of Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"8Department of Medical Oncology, Inselspital\/Bern University Hospital, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"9Department of Medicine III, University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-3274","authenticated-orcid":false,"given":"Karin","family":"Hohloch","sequence":"additional","affiliation":[{"name":"2Oncology and Hematology, Kantonsspital Graubuenden, Chur, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Lars","family":"Kienle","sequence":"additional","affiliation":[{"name":"2Oncology and Hematology, Kantonsspital Graubuenden, Chur, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Hess","sequence":"additional","affiliation":[{"name":"4Oncology\/Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden A.","family":"Moccia","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"9Department of Medicine III, University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Eckhardt","sequence":"additional","affiliation":[{"name":"3SAKK Coordinating Center, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-6559","authenticated-orcid":false,"given":"Stefanie","family":"Hayoz","sequence":"additional","affiliation":[{"name":"3SAKK Coordinating Center, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Forestieri","sequence":"additional","affiliation":[{"name":"10Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"10Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dirnhofer","sequence":"additional","affiliation":[{"name":"11Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-097X","authenticated-orcid":false,"given":"Luca","family":"Ceriani","sequence":"additional","affiliation":[{"name":"12Nuclear Medicine and PET-CT Center, Imaging Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;"},{"name":"15Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6704-9755","authenticated-orcid":false,"given":"Giulio","family":"Sartori","sequence":"additional","affiliation":[{"name":"13Lymphoma Genomics, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;"},{"name":"13Lymphoma Genomics, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[{"name":"14Institute of Experimental Cancer Research, CCC Ulm, University Hospital Ulm, Ulm, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;"},{"name":"8Department of Medical Oncology, Inselspital\/Bern University Hospital, Bern, Switzerland;"},{"name":"15Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"9Department of Medicine III, University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"issue":"31","key":"2022070615215703400_B1","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022070615215703400_B2","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet needs in the first-line treatment of follicular lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann Oncol."},{"issue":"23","key":"2022070615215703400_B3","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1200\/JCO.2018.79.3083","article-title":"Progress in advanced-stage follicular lymphoma","volume":"36","author":"Friedberg","year":"2018","journal-title":"J Clin Oncol."},{"issue":"9759","key":"2022070615215703400_B4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet."},{"issue":"9873","key":"2022070615215703400_B5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet."},{"issue":"19","key":"2022070615215703400_B6","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood."},{"issue":"14","key":"2022070615215703400_B7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"2022070615215703400_B8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2022070615215703400_B9","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol."},{"issue":"10","key":"2022070615215703400_B10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"2022070615215703400_B11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022070615215703400_B12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med."},{"issue":"12","key":"2022070615215703400_B13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med."},{"issue":"13","key":"2022070615215703400_B14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med."},{"issue":"22","key":"2022070615215703400_B15","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood."},{"issue":"15","key":"2022070615215703400_B16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022070615215703400_B17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol."},{"issue":"17","key":"2022070615215703400_B18","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"27","key":"2022070615215703400_B19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022070615215703400_B20","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann Oncol."},{"issue":"18","key":"2022070615215703400_B21","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood."},{"issue":"10","key":"2022070615215703400_B22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst."},{"issue":"9","key":"2022070615215703400_B23","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.humpath.2013.02.004","article-title":"The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-\u201cnegative\u201d grade 1\/2 follicular lymphomas","volume":"44","author":"Adam","year":"2013","journal-title":"Hum Pathol."},{"issue":"12","key":"2022070615215703400_B24","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia."},{"issue":"27","key":"2022070615215703400_B25","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022070615215703400_B26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2967\/jnumed.119.238923","article-title":"Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA Consortium","volume":"62","author":"Barrington","year":"2021","journal-title":"J Nucl Med."},{"issue":"4","key":"2022070615215703400_B27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s11307-020-01474-z","article-title":"Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma","volume":"22","author":"Burggraaff","year":"2020","journal-title":"Mol Imaging Biol."},{"issue":"6","key":"2022070615215703400_B28","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica."},{"issue":"17","key":"2022070615215703400_B29","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood."},{"issue":"30","key":"2022070615215703400_B30","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (ga101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol."},{"issue":"23","key":"2022070615215703400_B31","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood."},{"issue":"6","key":"2022070615215703400_B32","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1111\/bjh.16069","article-title":"Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma","volume":"186","author":"Blombery","year":"2019","journal-title":"Br J Haematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3911\/1905497\/advancesadv2021006520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3911\/1905497\/advancesadv2021006520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T15:22:51Z","timestamp":1657120971000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/13\/3911\/485207\/SAKK-35-15-a-phase-1-trial-of-obinutuzumab-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,7,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006520","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}